Telomir Pharmaceuticals, Inc.
TELOTelomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to address the biological drivers of aging and age-related diseases.
Earnings
Next report
Dec 2, 2026 (in a month)Competitors
Profile
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to address the biological drivers of aging and age-related diseases. The company's lead investigational candidate, Telomir-1, targets fundamental cellular processes such as metal-ion dysregulation, oxidative stress, and telomere integrity to restore cellular function. Its core value proposition lies in moving beyond symptom management to treat the underlying mechanisms of chronic conditions including Type 2 diabetes, oncology, and rare genetic disorders.
A preclinical-stage developer utilizing a novel mechanism of action focused on metal-ion homeostasis rather than traditional chelation.
FAQ
- What is Telomir Pharmaceuticals, Inc.'s market cap?
- Telomir Pharmaceuticals, Inc. (TELO) has a market capitalization of $71.0M and trades on NASDAQ.
- Who are Telomir Pharmaceuticals, Inc.'s competitors?
- Telomir Pharmaceuticals, Inc.'s key competitors include vTv Therapeutics Inc. Class A Common Stock, Compass Therapeutics, Inc. Common Stock, Spruce Biosciences, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Telomir Pharmaceuticals, Inc. partner with?
- Telomir Pharmaceuticals, Inc.'s notable partners include InSilico Trials, Recipharm, Smart Assays Biotechnologies Ltd., and others.
- What subsidiaries does Telomir Pharmaceuticals, Inc. have?
- Telomir Pharmaceuticals, Inc.'s subsidiaries include TELI Pharmaceuticals, Inc..
- Where is Telomir Pharmaceuticals, Inc. headquartered?
- Telomir Pharmaceuticals, Inc. is headquartered in United States of America. It has been publicly traded since 2024.